Janssen

INVEGA SUSTENNA

Manufacturer:

Janssen

Invega Sustenna HCPCS:

J2426

HCPCS Code Descriptor:

Injection, paliperidone palmitate extended release (invega sustenna), 1 mg

Category:

J Code

Invega Sustenna NDCs:

50458-0612-01, 50458-0611-01, 50458-0564-01, 50458-0563-01, 50458-0562-01, 50458-0561-01, 50458-0560-01

Primary Type:

Psychiatric

Generic/Specialty Status:

Single-Source

Route of Administration:

Intramuscular

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Invega Sustenna:

INVEGA SUSTENNA is a Psychiatric drug manufactured by Janssen and administered via the Intramuscular route of administration. The J Code: J2426 is aligned to the drug INVEGA SUSTENNA.

Invega Sustenna is an extended-release injectable medication used to treat schizophrenia and schizoaffective disorder in adults. It is administered via intramuscular injection by a healthcare provider. It may be used alone, or in combination with other medications to treat a variety of mental/mood disorders. Typically, the first two injections are given one week apart. After the initial doses, patients typically receive one injection per month.

ACCESS PRICING AND MORE BY REGISTERING

J2426 Added Date:

January 1, 2011

J2426 Effective Date:

July 1, 2023

J2426 Termination Date:

HCPCS Active

Invega Sustenna billing and coding information can be found through Janssen at the link below:
Invega Sustenna patient assistance information can be found through the Johnson and Johnson Patient Assistance Foundation at the URL: http://www.jjpaf.org/
INVEGA SUSTENNA prescribing information can be found at the link below:
Information regarding INVEGA SUSTENNA’s side effects can be found at MedlinePlus